ELECTROCORE INC (ECOR) Stock Price, Forecast & Analysis
USA - NASDAQ:ECOR - US28531P2020 - Common Stock
ECOR Key Statistics, Chart & Performance
The current stock price of ECOR is 5.83 USD. In the past month the price increased by 16.6%. In the past year, price decreased by -56.78%.
ECOR Latest News, Press Relases and Analysis
ECOR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.32 | 219.92B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.04 | 200.75B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.91 | 148.20B | ||
| SYK | STRYKER CORP | 27.03 | 136.11B | ||
| IDXX | IDEXX LABORATORIES INC | 56.18 | 56.68B | ||
| BDX | BECTON DICKINSON AND CO | 12.33 | 50.97B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.45 | 48.96B | ||
| RMD | RESMED INC | 25.4 | 36.70B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.92 | 33.35B | ||
| PODD | INSULET CORP | 75.61 | 22.51B | ||
| DXCM | DEXCOM INC | 29.57 | 21.57B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.94 | 17.53B |
Related stock screener links
About ECOR
Company Profile
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 73 full-time employees. The company went IPO on 2018-06-22. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
Company Info
ELECTROCORE INC
200 Forge Way, Suite 205
Rockaway NEW JERSEY 07866 US
CEO: Daniel S. Goldberger
Employees: 73
Phone: 19732900097
ELECTROCORE INC / ECOR FAQ
What does ECOR do?
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 73 full-time employees. The company went IPO on 2018-06-22. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
What is the stock price of ELECTROCORE INC today?
The current stock price of ECOR is 5.83 USD. The price decreased by -0.17% in the last trading session.
Does ECOR stock pay dividends?
ECOR does not pay a dividend.
What is the ChartMill rating of ELECTROCORE INC stock?
ECOR has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is ECOR stock listed?
ECOR stock is listed on the Nasdaq exchange.
Can you provide the number of employees for ELECTROCORE INC?
ELECTROCORE INC (ECOR) currently has 73 employees.
Can you provide the ownership details for ECOR stock?
You can find the ownership structure of ELECTROCORE INC (ECOR) on the Ownership tab.
ECOR Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ECOR. When comparing the yearly performance of all stocks, ECOR is a bad performer in the overall market: 82.34% of all stocks are doing better.
ECOR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ECOR. While ECOR seems to be doing ok healthwise, there are quite some concerns on its profitability.
ECOR Financial Highlights
Over the last trailing twelve months ECOR reported a non-GAAP Earnings per Share(EPS) of -1.62. The EPS increased by 26.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -91.02% | ||
| ROE | -1190.57% | ||
| Debt/Equity | 0 |
ECOR Forecast & Estimates
10 analysts have analysed ECOR and the average price target is 21.5 USD. This implies a price increase of 268.81% is expected in the next year compared to the current price of 5.83.
For the next year, analysts expect an EPS growth of -3.65% and a revenue growth 21.64% for ECOR